Clinical Implications of <i>TP53</i> Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate DatabaseTariq Kewan, Amer M. Zeidan, Mikkael A. Sekeres et al.|Blood|2023Cited by 1
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)Tariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular DataTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1